Setup: HNGE at $33, down 32% in one month following lockup expiration and growth deceleration. Trading at 17x forward P/E, RSI 22, with 31% FCF margins and 25% guided growth. Analyst consensus $63 mean target (89% upside). All 17 analysts rate buy/overweight, zero sells.

What Happened:

IPO lockup expired November 18, 2025 (180 days post-IPO). CEO Perez sold 166K shares via 10b5-1 plan in December and January ($7.7M total), with CFO and President also selling. Stock crushed from $48 to $33. This is mechanical post-lockup selling, not fundamental deterioration.

Q4 earnings beat across the board — $171M revenue (+46% YoY), full year $588M (+51% YoY), $180M FCF (31% margin, hit their 30% IPO target in 7 months), Rule of 40 score 81. But FY26 guidance decelerated to 25% growth from 51%, sparking a healthcare platform selloff pattern.

The AI Efficiency Flywheel (Primary Source):

From the Q4 transcript, CEO Perez:

"In 2025, we served 47% more members while keeping care team costs flat. One major driver of this improvement was our successful rollout of automated AI-powered communications for routine messaging... Robin, our AI care assistant... members engaging with Robin are giving it a 92% positive rating... we're currently planning to keep the size of the care team flat once again in 2026."

CFO Budge added: "Operating costs as % of revenue dropped from 84% to 64% (2000bps). Gross margin improved from 78% to 83% YoY."

This is real unit economics improvement. Care team costs decoupling from member growth. Engineer productivity doubled (2x PRs/engineer/week) from AI tooling. This is a structural margin story, not a narrative.

What's Priced:

Market repricing HNGE from hyper-growth to "merely" 25% grower. The deceleration is structural — larger revenue base, H2 selling / H1 go-live cycle. But the economics are elite: 97% client retention, 83% gross margins, 31% FCF margins at scale, employer B2B with near-perfect retention.

At 17x P/E on 25% growth with those margins, this is a quality compounder at a dislocation price. Comparable SaaS/platform companies with these economics trade 30-50x.

The DOCS Comparison:

Doximity (DOCS) just got annihilated in the same timeframe — down 38% after earnings on weak guidance (Q4 guided to 4% growth vs 10% in Q3, missed consensus by $6M). AI infrastructure costs compressed margins, and pharma clients went "wait-and-see." Analysts slashed targets (Truist cut from $62 to $37). DOCS now RSI 8.8, trading at 6% of 52-week range.

The market is killing healthcare platforms that decelerate, full stop. HNGE's 51% → 25% triggered the same reflex. But the fundamentals are opposite:

  • DOCS: AI costs rising, margins compressing (93% → 91% gross margin)

  • HNGE: AI driving margin expansion (78% → 83% gross margin, 2000bp opex leverage)

  • DOCS: Cyclical pharma clients pulling back

  • HNGE: Employer B2B, 97% retention, 53% of Fortune 100

  • DOCS: Growth decelerating to 4%

  • HNGE: Decelerating to 25% (still strong, just off a larger base)

This is sector contagion, not company-specific deterioration. HNGE is being tarred with the healthcare platform brush despite fundamentally different economics.

What You Don't Know:

  1. Lockup selling exhaustion — CEO sold two tranches post-lockup (Dec/Jan). How much remains? When does mechanical selling exhaust? This is the key timing variable for entry. The $250M buyback authorized in November suggests management saw this coming, but timing matters.

  2. Competitive dynamics — Sword Health, Omada Health, Kaia Health in digital MSK. Worker flagged this gap. No one has quantified HNGE's moat vs peers. The 97% retention and Fortune 100 penetration suggest strong position, but competitive win rates and market share trends matter.

  3. Factor decomposition — Idio vol 63.4%, below the 75% threshold. A meaningful chunk of HNGE's variance is systematic (healthcare platform beta, not company-specific alpha). Need to decompose market/sector/company components before sizing. If you're paying for healthcare platform beta that's repricing sector-wide, you want to know that.

  4. Hinge Select and Medicare ramp — Management says "no revenue until 2027+" but 85% of Hinge Select members moving to conservative care (avoiding surgery) is a real unit economics wedge. When does this inflect from "interesting optionality" to "material revenue driver"? The two-sided marketplace build takes years, but once scaled, it's a moat. Timeline matters.

Verdict:

This is a single-ticker signal convergence — lockup-driven dislocation on a quality business with mechanical (not fundamental) selling pressure. The combination of signals is asymmetric:

  • RSI 22 (extreme oversold)
  • 17x forward P/E on 25% growth with 31% FCF margins
  • 97% client retention
  • AI efficiency flywheel (real, quantified, structural)
  • Mechanical post-lockup selling, not fundamental deterioration
  • 89% upside to analyst consensus ($63 mean target)
  • Cheap IV (35th percentile — options mispricing potential snap-back)
  • 12.3% short interest (fuel for squeeze if lockup exhausts)

The key variable is lockup exhaustion timing. Once mechanical selling stops, this setup has the profile of a quality compounder repricing from growth-panic lows. The DOCS comparison is the counter-narrative risk — market is punishing ALL healthcare platforms that decelerate, regardless of fundamentals. But HNGE's economics (margin expansion, B2B retention, structural cost leverage) are fundamentally different.

Not a thesis yet. But worth tracking as lockup pressure exhausts. If you can time the end of mechanical selling + catch a sector rotation back into quality healthcare platforms, the asymmetry is there. At $33 with these economics, this is either a steal or the market sees something structurally broken that isn't in the transcript. The data says steal. The sector selloff says caution.

Sources: